FTC Pushes For Watson CEO To Testify In Provigil Probe

Law360, New York (June 1, 2010, 3:15 PM EDT) -- The Federal Trade Commission has again urged a federal court to force the CEO of Watson Pharmaceuticals Inc. to testify about a settlement in a Cephalon Inc. patent infringement suit over narcolepsy treatment Provigil that may have stalled generic competition for the drug.

The commission lodged a memorandum in support of its petition for an order enforcing its July 22 subpoena of Watson CEO Paul M. Bisaro on Friday in the U.S. District Court for the District of Columbia, firing back at the drugmaker's contention that...
To view the full article, register now.